Meyer-Lehnert H, Jahnecke C, Kappes-Horn K, Kramer H J
Medizinische Universitäts-Poliklinik Bonn.
Klin Wochenschr. 1991;69 Suppl 24:45-9.
In order to investigate renin- and angiotensin-independent mechanisms of the angiotensin converting enzyme (ACE) inhibitor ramipril we examined the effects of ramiprilat on calcium mobilization in cultured vascular smooth muscle cells. Ramiprilat (10(-7) M) induced a slow increase of basal [Ca2+]i from 52 +/- 7 nM to 162 +/- 12 nM (p less than .001). This increase of basal [Ca2+]i was associated with contraction of vascular smooth muscle cells as assessed by microscopy in vitro. While ramiprilat itself induced an increase of basal [Ca2+]i, the Ca(2+)-mobilizing effect of angiotensin II (AII) was blunted in the presence of the ACE inhibitor (659 +/- 38 nM vs 360 +/- 45 nM, p less than .001). The calcium channel blocker verapamil did not affect the stimulatory effect of ramiprilat on basal [Ca2+]i. The intracellular Ca2+ antagonist TMB 8 attenuated the ramiprilat-induced increase of basal [Ca2+]i (162 +/- 12 nM vs 101 +/- 14 nM, p less than .05). In the present study, the effect of ramiprilat on [Ca2+]i was not blocked by inhibition of prostaglandin synthesis by meclofenamate (10(-5) M); however, this finding does not rule out in vivo effects of ramiprilat-stimulated prostaglandins. These results suggest that ramipril affects Ca2+ kinetics in vascular smooth muscle cells. Ramiprilat-induced contraction of cultured smooth muscle cells may not be relevant in vivo, but the increase of basal [Ca2+]i by ramiprilat may reflect a "reset" of the cellular Ca(2+)-mobilizing mechanism or a depletion of cellular Ca2+ stores and may thus explain the attenuation of the Ca(2+)-mobilizing effect of AII. This mechanism may result in a decrease of vasopressor-dependent vascular tone in vivo and may contribute to the vasodilatory effect of ramipril.
为了研究血管紧张素转换酶(ACE)抑制剂雷米普利的非肾素和血管紧张素依赖性机制,我们检测了雷米普利拉对培养的血管平滑肌细胞钙动员的影响。雷米普利拉(10⁻⁷ M)使基础细胞内钙离子浓度([Ca²⁺]i)从52±7 nM缓慢升高至162±12 nM(p<0.001)。基础[Ca²⁺]i的这种升高与体外显微镜观察评估的血管平滑肌细胞收缩有关。虽然雷米普利拉本身可诱导基础[Ca²⁺]i升高,但在ACE抑制剂存在的情况下,血管紧张素II(AII)的钙动员作用减弱(659±38 nM对360±45 nM,p<0.001)。钙通道阻滞剂维拉帕米不影响雷米普利拉对基础[Ca²⁺]i的刺激作用。细胞内钙拮抗剂TMB 8减弱了雷米普利拉诱导的基础[Ca²⁺]i升高(162±12 nM对101±14 nM,p<0.05)。在本研究中,甲氯芬那酸(10⁻⁵ M)抑制前列腺素合成并未阻断雷米普利拉对[Ca²⁺]i的作用;然而,这一发现并不能排除雷米普利拉刺激前列腺素在体内的作用。这些结果表明雷米普利影响血管平滑肌细胞中的钙动力学。雷米普利拉诱导培养的平滑肌细胞收缩在体内可能无关,但雷米普利拉引起的基础[Ca²⁺]i升高可能反映了细胞钙动员机制的“重置”或细胞钙储存的耗竭,因此可能解释了AII钙动员作用的减弱。这种机制可能导致体内血管升压依赖性血管张力降低,并可能有助于雷米普利的血管舒张作用。